A Phase 1b clinical trial evaluating GlaxoSmithKline (GSK)’s belantamab mafodotin, in combination with SpringWorks Therapeutics’ nirogacestat, in people with relapsed or refractory multiple myeloma, has dosed its first patient, SpringWorks announced. The safety and preliminary effectiveness of this combination are being assessed as a sub-study in GSK’s ongoing DREAMM-5 platform trial (NCT04126200). “We are delighted to have reached this important milestone of dosing the first patient in this collaborative trial with GSK,” Saqib Islam, SpringWorks’ CEO,…
You must be logged in to read/download the full post.
The post First Patient Dosed in Trial Testing Belantamab Mafodotin, Nirogacestat Combo in RRMM Patients appeared first on BioNewsFeeds.